On April 12, 2018 Seattle Genetics, Inc. (Nasdaq: SGEN) reported data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline (Press release, Seattle Genetics, APR 12, 2018, View Source;p=RssLanding&cat=news&id=2342255 [SID1234525283]). Data include preclinical and clinical advances with ADCETRIS (brentuximab vedotin), ladiratuzumab vedotin, SGN-CD48A and SGN-2FF. Additionally, Seattle Genetics will present the first preclinical data describing the novel empowered antibody SEA-BCMA. These data will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 being held April 14-18, 2018 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are an emerging multi-product company, advancing a substantial pipeline of targeted therapies for patients with solid tumors and blood cancers," said Dennis Benjamin, Ph.D., Senior Vice President of Research at Seattle Genetics. "New data featured in nine presentations underscore our commitment to scientific innovation and the needs of patients. These data presentations highlight the potential combination of ADCs with checkpoint inhibitors, novel ADC payloads, antibody masking technologies and progress with our immuno-oncology program, SGN-2FF. We are also presenting preclinical data for our new multiple myeloma program, SEA-BCMA, which has a phase 1 study scheduled to start this year."

Abstracts can be found at www.aacr.org and include the following:

An oral presentation and poster presentation on Sunday and Monday, April 15 and 16, 2018, respectively (Abstracts #930, 2803), will showcase preclinical data evaluating proprietary NAMPT inhibitors and auristatins as ADC payloads. The data show NAMPT inhibitors have a unique mechanism of action and encouraging therapeutic window. Preclinical data also describe the development of novel auristatin payloads with potential application across multiple tumor types.
An innovative approach to masking antibodies for tumor specific activation will be featured in a poster presentation on Sunday, April 15, 2018 (Abstract #250). Preclinical data demonstrate that coiled-coil masked antibodies and ADCs show improved tolerability and equivalent antitumor activity compared to unmasked counterparts. The data suggest this technology may be applied to a range of antibodies or ADCs and could enable their development against previously inaccessible cancer targets.
The novel preclinical program SEA-BCMA will be highlighted in a poster presentation on Tuesday, April 17, 2018 (Abstract #3833). The cell surface protein BCMA is expressed on cells of several cancer types, including multiple myeloma and other B cell malignancies. SEA-BCMA is an antibody empowered using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody effector functions. The preclinical data support initiation of a phase 1 trial for multiple myeloma, which is planned for 2018.
Clinical biomarker data from a phase 1 trial evaluating the novel immuno-oncology agent SGN-2FF in patients with advanced solid tumors will be shown in a poster presentation on Wednesday, April 18, 2018 (Abstract #5551). The preliminary data demonstrate the biological effects of SGN-2FF and support further development of this novel immuno-oncology agent.
Three poster presentations on Monday and Wednesday, April 16 and 18, 2018 (Abstracts #1789, 2742, and 5619) will highlight preclinical data evaluating the ability of ADCETRIS, ladiratuzumab vedotin and SGN-CD48A, each of which are auristatin-based ADCs, to elicit additional mechanisms of action, including immunogenic cell death. These data support clinical evaluation in combination with checkpoint inhibitors. ADCETRIS and ladiratuzumab vedotin are being evaluated in combination with checkpoint inhibitors in multiple ongoing clinical trials.

On April 12, 2018 Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported it will be presenting preclinical data from its SIRPaFc immune checkpoint inhibitor programs, TTI-621 and TTI-622, at the 109th Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Trillium Therapeutics, APR 12, 2018, View Source [SID1234525284]). The meeting will be held April 14-18 in Chicago, IL. Details of the poster presentations are listed below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis"
Presenter: Julia Bershadsky Izrailit, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr 16, 2018 from 1:00 p.m. – 5:00 p.m.
CT Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2720

Title: "TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with anti-tumor antibodies in both hematological and solid tumor models"
Presenter: Gloria Lin, Ph.D., Trillium Therapeutics Inc.
Date and Time: Apr. 16, 2018 from 1:00 p.m. – 5:00 p.m. CT
Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Abstract Number: 2709

On April 12, 2018 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release first-quarter 2018 financial results before the market opens on Thursday, April 26, 2018, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, APR 12, 2018, View Source;p=RssLanding&cat=news&id=2342215 [SID1234525285]). To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 9889627.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(PRNewsfoto/West Pharmaceutical Services, I)

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, May 3, 2018, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 9889627.

On April 12, 2018 Active Biotech (NASDAQ STOCKHOLM: ACTI) reported that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in Chicago on April 14-18, 2018 (Press release, Active Biotech, APR 12, 2018, View Source [SID1234525482]). The poster Naptumumab Estafenatox Induces T cells Tumor Recognition, Turning anti-PD1 Unresponsive "Cold" Tumors into "Hot" Responsive Tumors will be presented between 1:00 p.m. and 5:00 p.m. local time on April 16, 2018, at the session "Immune Checkpoints 2". The data to be presented demonstrates a synergistic anti-tumor effect when ANYARA is combined with a PD-1 checkpoint inhibitor in several different tumor models that are marginally responsive to PD-1 inhibition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Checkpoint inhibitors are drugs that unleash an immune system attack against tumor cells. It is well established that a key factor that limits the effectiveness of checkpoint inhibition is tumor recognition. ANYARA is a Tumor Targeted Superantigen (TTS) that enhances the ability of the immune system to recognize and kill the tumors and is therefore attractive for combination therapy to enhance the efficacy of checkpoint inhibition.

"We are enthusiastic that our partner NeoTX has been selected to present these important data showing that ANYARA, through its tumor-targeted mode of action, enhances the effect of PD-1 inhibition and thereby potentially increases the clinical benefit of such treatment in the long term," says Helén Tuvesson, CEO of Active Biotech.

A summary of the poster presentation will be published at: View Source!/4562/presentation/9330

About ANYARA

ANYARA is a Tumor Targeting Superantigen (TTS) that enhances the ability of the immune system to recognize and kill tumors. Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer. Clinically, the development of ANYARA has focused on cancer forms with a high medical need. Positive data was reported from clinical Phase 1 and 2/3 studies in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent and in combination with an established tumor therapy in patients with advanced cancer. Preparations for a clinical trial in combination with a checkpoint inhibitor are ongoing.

Lund, April 12, 2018
Active Biotech AB (publ)

For further information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 20 95
Email: [email protected]

Hans Kolam, CFO
Tel. +46 46 19 20 44
Email: [email protected]

On April 12, 2018 Athersys, Inc. (Nasdaq:ATHX) reported that it will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results (Press release, Athersys, APR 12, 2018, View Source [SID1234525286]). Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date May 10, 2018
Time 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 1189915
Live webcast www.athersys.com under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 1189915.